Review
Pharmacology & Pharmacy
Abhijeet Dhulap, Paromita Banerjee
Summary: Tuberculosis caused by Mycobacterium tuberculosis is a major cause of mortality worldwide, and the discovery of new drug targets and drugs for drug-resistant forms of bacteria is a key focus in the fight against TB. ATP synthase has been identified as a key target for MDR-TB, and research on diarylquinoline class of inhibitors is providing insights into potential clinical relevance for treating drug-resistant TB.
CURRENT DRUG TARGETS
(2021)
Article
Microbiology
Kone Kaniga, Rumina Hasan, Ruwen Jou, Edita Vasiliauskiene, Charoen Chuchottaworn, Nazir Ismail, Beverly Metchock, Skaidrius Miliauskas, Nguyen Viet Nhung, Camilla Rodrigues, Soyoun Shin, Hulya Simsek, Saijai Smithtikarn, Anh Le Thi Ngoc, Jirakan Boonyasopun, Mubin Kazi, Seungmo Kim, Phalin Kamolwat, Greta Musteikiene, Catherine Ann Sacopon, Sabira Tahseen, Laima Vasiliauskaite, Mei-Hua Wu, Shaheed Vally Omar
Summary: Bedaquiline Drug Resistance Emergence Assessment in Multidrug-resistant tuberculosis (MDR-TB) (DREAM) conducted a 5-year surveillance study across 11 countries, finding low resistance rates to Bedaquiline and no treatment-limiting patterns of cross-resistance or coresistance with key TB drugs.
JOURNAL OF CLINICAL MICROBIOLOGY
(2022)
Letter
Immunology
James Millard, Stephanie Rimmer, Camus Nimmo, Max O'Donnell
Summary: New classes of antitubercular drugs, diarylquinolines and nitroimidazoles, have been effective in treating drug-resistant tuberculosis. However, a case of bedaquiline and delamanid resistance in a patient with extensively drug-resistant tuberculosis and HIV has been reported in South Africa.
EMERGING INFECTIOUS DISEASES
(2023)
Review
Pharmacology & Pharmacy
Yaxin Wu, Yuening Zhang, Yingying Wang, Jiaqi Wei, Wenjing Wang, Wenshan Duan, Yakun Tian, Meixin Ren, Zhen Li, Wen Wang, Tong Zhang, Hao Wu, Xiaojie Huang
Summary: The study aimed to evaluate the effectiveness of second-line anti-TB treatment and determine which drugs can achieve the greatest clinical benefit for DR-TB-HIV patients. The results showed that BDQ and LZD-based regimens, along with the use of at least two Group A drugs, were associated with a higher treatment success rate. Additionally, a higher baseline CD4 T-cell count was also correlated with higher treatment success rates.
PHARMACOLOGICAL RESEARCH
(2022)
Article
Infectious Diseases
Rao Nargis Jahan, Zafar Khan, Md. Sayeed Akhtar, Mohd Danish Ansari, Pavitra Solanki, Farhan J. Ahmad, Mohd Aqil, Yasmin Sultana, Neeraj Dhar
Summary: This study successfully enhanced the biopharmaceutical properties of bedaquiline by developing a QbD-based self-nanoemulsifying drug delivery system, providing a promising strategy for potential cost and time savings.
Article
Infectious Diseases
Simon Tiberi, Michael J. Vjecha, Adam Zumla, Jessica Galvin, Giovanni Battista Migliori, Alimuddin Zumla
Summary: The global report estimates a high number of MDR-TB cases, emphasizing the need for improving screening, diagnostic, treatment, and follow-up services; New TB drugs are showing promising results in improving cure rates, with a more tolerable six-month oral treatment regimen; The COVID-19 pandemic is negatively impacting TB services, requiring increased investment and expansion of TB treatment services.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Respiratory System
Palwasha Y. Khan, Molly F. Franke, Catherine Hewison, Kwonjune J. Seung, Helena Huerga, Sidney Atwood, Saman Ahmed, Munira Khan, Tanha Sultana, Mohammad Manzur-Ul-Alam, Luan N. Q. Vo, Leonid Lecca, Kalkidan Yae, Serik Kozhabekov, Meseret Tamirat, Alain Gelin, Stalz C. Vilbrun, Marina Kikvidze, Jamil Faqirzai, Abdullaat Kadyrov, Alena Skrahina, Anita Mesic, Nana Avagyan, Mathieu Bastard, Michael L. Rich, Uzma Khan, Carole D. Mitnick
Summary: This study compared the effectiveness of an injectable regimen to an all-oral regimen in patients with drug-resistant tuberculosis who received bedaquiline and/or delamanid as part of their treatment. The results showed no significant difference in culture conversion within 6 months between those who received an injectable and those who did not, except for a small increase in conversion frequency among HIV-positive patients receiving an injectable regimen. Further research is needed on the potential contribution of injectable agents in the treatment of drug-resistant tuberculosis among HIV-positive patients.
EUROPEAN RESPIRATORY JOURNAL
(2022)
Article
Infectious Diseases
R. Moodliar, V. Aksenova, M. V. G. Frias, J. van de Logt, S. Rossenu, E. Birmingham, S. Zhou, G. Mao, N. Lounis, C. Kambili, N. Bakare
Summary: The TMC207-C211 study evaluated the pharmacokinetics and safety of bedaquiline in children with multidrug-resistant tuberculosis, showing comparable results to adults in terms of efficacy and safety after 24 weeks of treatment.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
(2021)
Article
Infectious Diseases
Danilo Buonsenso, Giovanni Autore, Francesca Cusenza, Lucrezia Passadore, Francesca Bonanno, Susanna Esposito
Summary: The spread of drug-resistant tuberculosis (TB) has led to the development of new drugs and the reappraisal of old drugs. Ensuring access to child-friendly medicines for drug-resistant TB is crucial for reducing the global burden of TB. This perspective highlights the need for child-friendly formulations of second-line drugs to improve adherence to treatment regimens and prevent the development of additional drug resistance.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2023)
Review
Medicine, General & Internal
Anuradha T. Deshkar, Prashant A. Shirure
Summary: Bedaquiline, a new drug for the treatment of multidrug-resistant tuberculosis, has a unique mechanism of action and has shown promising results in clinical trials.
CUREUS JOURNAL OF MEDICAL SCIENCE
(2022)
Article
Materials Science, Biomaterials
Madhavi Bhandari, Hector Soria-Carrera, Jens Wohlmann, Nils-Jorgen Knudsen Dal, Jesus M. de la Fuente, Rafael Martin-Rapun, Gareth Griffiths, Federico Fenaroli
Summary: Nanoparticles have shown promise as an alternative method for drug delivery in tuberculosis treatment, improving efficacy and reducing toxicity.
BIOMATERIALS SCIENCE
(2023)
Editorial Material
Immunology
Takashi Yoshiyama, Akiko Takaki, Akio Aono, Satoshi Mitarai, Masao Okumura, Ken Ohta, Seiya Kato
Summary: This study reported a clinical case of simultaneous acquisition of resistance to bedaquiline and delamanid in Mycobacterium tuberculosis, with specific nucleotide insertions identified through whole genome sequencing. The minimum inhibitory concentrations for bedaquiline and delamanid were determined to be 0.25 μg/mL and >2.0 μg/mL, respectively.
CLINICAL INFECTIOUS DISEASES
(2021)
Review
Immunology
Hanzhao Zhu, Xintong Zhou, Zengfang Zhuang, Lianju Li, Jing Bi, Kaixia Mi
Summary: Tuberculosis (TB) remains a significant public health issue, especially among children who often receive insufficient diagnosis and treatment. The emergence of drug-resistant strains has further complicated the situation, with limited effectiveness of current treatments. New drugs like bedaquiline and delamanid show promise in treating drug-resistant TB, but the lack of clinical data in children hinders the development of child-friendly formulations. This paper provides a comprehensive review of the development, mechanisms, efficacy, safety considerations, and current use of these drugs in treating drug-resistant TB in children.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2023)
Article
Microbiology
Sheng-Han Wu, Hsin-Hua Chan, Hseuh-Chien Hsiao, Ruwen Jou
Summary: This study found that redefining the intermediate susceptibility category for BDQ resistance and conducting genotypic analyses for MGIT-BDQ borderline resistance isolates are recommended to better manage drug-resistant tuberculosis cases. Additionally, the study observed that Rv0678 mutations were not a robust marker of BDQ resistance and were not associated with treatment outcomes in BDQ-resistant patients without exposure.
FRONTIERS IN MICROBIOLOGY
(2021)
Article
Infectious Diseases
S. Oelofse, A. Esmail, A. H. Diacon, F. Conradie, O. Olayanju, N. Ngubane, P. Howell, D. Everitt, A. M. Crook, C. M. Mendel, G. H. Wills, M. Olugbosi, A. del Parigi, E. Sun, A. Calatroni, M. Spigelman, K. Dheda
Summary: The study showed that the 6-9 month oral three-drug Nix regimen (bedaquiline, pretomanid and linezolid [BPaL]) had significantly better outcomes for drug-resistant TB patients compared to conventional regimens containing bedaquiline and linezolid. Despite higher baseline bacterial load and prior second-line drug exposure, the BPaL regimen showed improved culture conversion time, time to unfavorable outcome, and time to death. Prospective controlled studies are needed for definitive answers to the question.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
(2021)
Review
Pharmacology & Pharmacy
Brooke L. Griffin, Rebecca H. Stone, Shareen Y. El-Ibiary, Sarah Westberg, Kayce Shealy, Alicia Forinash, Abigail Yancey, Kathleen Vest, Lamis R. Karaoui, Sally Rafie, Cheryl Horlen, Nicole Lodise, Nicole Cieri-Hutcherson, Sarah McBane, Anahit Simonyan
ANNALS OF PHARMACOTHERAPY
(2018)
Article
Public, Environmental & Occupational Health
Lamis R. Karaoui, Mary E. Deeb, Layal Nasser, Souheil Hallit
Article
Medicine, Research & Experimental
Lamis R. Karaoui, Samah Tawil, Pascale Salameh, Nibal Chamoun
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
(2019)
Article
Health Care Sciences & Services
Lamis R. Karaoui, Nibal Chamoun, Jessica Fakhir, Wael Abi Ghanem, Sarah Droubi, Abdul Rahman Diab Marzouk, Nabila Droubi, Hiba Masri, Elsy Ramia
BMC HEALTH SERVICES RESEARCH
(2019)
Review
Pharmacology & Pharmacy
Hanine Mansour, Ahmad El Ouweini, Elias B. Chahine, Lamis R. Karaoui
Summary: Imipenem/cilastatin/relebactam is a new antibiotic combination approved for the treatment of infections caused by MDR gram-negative bacteria, excluding certain resistant strains. Clinical trials have demonstrated its efficacy and safety, with common adverse events including anemia, elevated liver enzymes, and nausea.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
(2021)
Article
Health Care Sciences & Services
Lamis R. Karaoui, Elsy Ramia, Hanine Mansour, Nisrine Haddad, Nibal Chamoun
Summary: Limited data in Lebanon assesses the impact of supplemental education on anticoagulant use. This study aimed to evaluate the effects of pharmacist-conducted anticoagulation education on bleeding and readmission rates. Results showed that pharmacist counseling increased patient communication with healthcare providers.
BMC HEALTH SERVICES RESEARCH
(2021)
Editorial Material
Pharmacology & Pharmacy
Brittany D. Bissell, Jackie P. Johnston, Rebecca R. Smith, Andrea Sikora Newsome, Melissa L. Thompson Bastin, Jacinda Abdul-Mutakabbir, Ashley Barlow, Brooke Barlow, Karen Berger, Jessica R. Crow, Deepali Dixit, Judith Jacobi, Lamis R. Karaoui, Tyree H. Kiser, Jill Kolesar, Susannah E. Koontz, T. Joseph Mattingly, Chelsea Mitchell, Alexsandra Nilges, Megan A. Rech, Mojdeh S. Heavner
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
(2021)
Article
Health Policy & Services
Ahmad El Ouweini, Lamis R. Karaoui, Nibal Chamoun, Chahine Assi, Kaissar Yammine, Elsy Ramia
Summary: This study aimed to assess the impact of pharmacist-conducted medication reconciliation in orthopedic surgical department in Lebanon. The results showed that pharmacy-led medication reconciliation upon admission can reduce reconciliation errors and improve medication safety. It also found that the number of home medications was significantly associated with the number of reconciliation errors.
JOURNAL OF PHARMACEUTICAL POLICY AND PRACTICE
(2021)
Review
Pharmacology & Pharmacy
Kylie N. Barnes, Lauren D. Leader, Nicole E. Cieri-Hutcherson, Julie Kelsey, Mary F. Hebert, Lamis R. Karaoui, Sarah McBane
Summary: Complications during the peripartum period may arise from preexisting conditions or conditions induced by pregnancy, affecting pharmacotherapy management. Management of medication during late pregnancy and delivery requires careful consideration of changing hormones, hemodynamic status, pharmacokinetics, and concerns for potential maternal and/or fetal morbidity.
JOURNAL OF PHARMACY PRACTICE
(2022)
Review
Pharmacology & Pharmacy
Nicole E. Cieri-Hutcherson, John Brock Harris, Lamis R. Karaoui, Lauren Lakdawala, Nicole M. Lodise, Rebecca H. Stone, Veronica Vernon
Summary: Infertility is a significant public health concern in the United States, and pharmacists play a crucial role in providing support and education in infertility management, including education, referrals, and management options.
JOURNAL OF PHARMACY PRACTICE
(2021)
Article
Pharmacology & Pharmacy
Kelly E. Caudle, Roseann S. Gammal, Jason H. Karnes, Janna Afanasjeva, Keri C. Anderson, Erin F. Barreto, Craig Beavers, Shubha Bhat, Kara L. Birrer, Elias B. Chahine, Christopher R. Ensor, Stephanie A. Flowers, Christine M. Formea, Jomy M. George, Rena A. Gosser, Mary F. Hebert, Lamis R. Karaoui, Jimmi Hatton Kolpek, James C. Lee, Jonathan G. Leung, Angela Q. Maldonado, Molly G. Minze, Rebecca A. Pulk, Chasity M. Shelton, Maria Sheridan, Michael A. Smith, Scott Soefje, Eglis Tellez-Corrales, Christine M. Walko, Larisa H. Cavallari
JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY
(2019)
Article
Pharmacology & Pharmacy
Katia Iskandar, Etwal Bou Raad, Souheil Hallit, Nibal Chamoun, Ulfat Usta, Youssef Akiki, Lamis R. Karaoui, Pascale Salameh, Rony M. Zeenny
PHARMACY PRACTICE-GRANADA
(2018)
Meeting Abstract
Pharmacology & Pharmacy
Lamis Karaoui, Maha Habre, Rudy Bahri, Elias Chahine, Nelly El-Chammas Issa, Nadia Asmar
Review
Pharmacology & Pharmacy
Lamis R. Karaoui, Hanine Mansour, Elias B. Chahine
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
(2017)
Article
Pharmacology & Pharmacy
Nibal Chamoun, Ulfat Usta, Lamis R. Karaoui, Pascale Salameh, Souheil Hallit, Patricia Shuhaiber, Anna-Maria Henaine, Youssef Akiki, Rony M. Zeenny, Katia Iskandar